Advertisement
UK markets open in 5 hours 28 minutes

  • NIKKEI 225

    38,317.18
    +765.02 (+2.04%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.30
    -0.06 (-0.07%)
     

  • GOLD FUTURES

    2,334.50
    -7.60 (-0.32%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,587.43
    -170.60 (-0.32%)
     

  • CMC Crypto 200

    1,435.82
    +21.06 (+1.49%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Costly leukaemia pill wins UK green light after price cut

Reuters - UK Focus

LONDON, Nov 25 (Reuters) - A costly blood cancer pill sold in Europe by Johnson & Johnson (NYSE: JNJ - news) will be made routinely available to certain patients in Britain with chronic lymphocytic leukaemia, after the U.S. company agreed to cut the price.

The National Institute for Health and Care Excellence (NICE (LSE: 0FEW.L - news) ) said on Friday the discount offered by J&J meant it could now recommend Imbruvica as offering value for money to the state-run health service.

The move comes as NICE reappraises all drugs covered by the Cancer Drugs Fund (CDF), which was overhauled earlier this year.

Other companies including Novartis (IOB: 0QLR.IL - news) , Pfizer (NYSE: PFE - news) , Bristol-Myers Squibb and Eisai have also offered discounts to ensure drugs previously covered by the CDF are used routinely on the National Health Service (NHS).

ADVERTISEMENT

The list price for a year's supply of Imbruvica is more than 55,000 pounds ($68,000) per patient. The size of the NHS discount is being kept confidential.

($1 = 0.8030 pounds) (Reporting by Ben Hirschler; Editing by Adrian Croft)